Sara Tolaney
LightNews LightNews
stolaney1.bsky.social
Sara Tolaney
@stolaney1.bsky.social
410 followers 71 following 1 posts
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Posts Replies Media Videos
stolaney1.bsky.social
Thank you so mcuh @stoverlab.bsky.social for the phenomenal keynote lecture-- you have built an incredible translational research infrastructure and team!
It was wonderful to have you back in Boston!

@dfcibreastonc.bsky.social
stoverlab.bsky.social Daniel Stover, MD, FASCO @stoverlab.bsky.social · Mar 28
Thank you to @stolaney1.bsky.social @dfcibreastonc.bsky.social for inviting me to give the J. Dirk Iglehart, M.D. Visiting Scholar Lecture at the DF/HCC Breast & Gynecologic Cancer Symposium.

Incredible science, great friends & connections - what an honor!

www.dfhcc.harvard.edu/events/dfhcc...
March 29, 2025 at 12:34 AM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
January 15, 2025 at 3:59 PM
Reposted by Sara Tolaney
drsgraff.bsky.social
Congratulations all!! @stolaney1.bsky.social @lymphomadoc.bsky.social @ryannipp.bsky.social and more! #FASCO
ascocancer.bsky.social American Society of Clinical Oncology @ascocancer.bsky.social · Feb 6
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.

Learn More: brnw.ch/21wQwer
February 7, 2025 at 10:42 AM
Reposted by Sara Tolaney
marleenkok.bsky.social
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
dfcibreastonc.bsky.social Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Feb 7
📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
February 7, 2025 at 10:00 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Don't miss this recent Current Oncology Reports review on #AntibodyDrugConjugates in #BreastCancer: The Road Towards Biologically-Informed Selection and Sequencing pubmed.ncbi.nlm.nih.gov/39786525/
@ptarantinomd.bsky.social @ilanaschlam.bsky.social @stolaney1.bsky.social #AnaGarridoCastro
February 13, 2025 at 9:34 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Dr. Paolo Tarantino (@ptarantinomd.bsky.social)
and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss efforts to create consensus based #BreastCancer Treatment Guidelines, which are meant to encourage uniform, evidence-based practice. Read here ⬇️
physicianresources.dana-farber.org/symposium/br...
February 26, 2025 at 6:37 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Join Dr. Sara Tolaney (@stolaney1.bsky.social) tomorrow at #SABCS24 for an insightful #CareerDevelopment session, focused on early funding for research. Dr. Tolaney will discuss the importance of having foundation and community program support.
🗓️ Dec 10th
⏰12:00–1:45 pm CST (1:00 pm EST)
📍Rm 221ABC
December 9, 2024 at 7:50 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Dr. Sara Tolaney (@stolaney1.bsky.social) will moderate the #SABCS24 poster spotlight session 3 on novel therapeutics in #BreastCancer on Wed Dec 11th – don’t miss it!

🗓️ Wednesday, December 11th
⏰ 7:00 – 8:30 am CST (8:00 – 9:30 am EST)
📍 Stars at Night 1-2
December 10, 2024 at 5:55 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Dr. Sara Tolaney (@stolaney1.bsky.social) offered great tips and strategies for obtaining research funding from foundations and community programs in the #SABCS24 Career Development Session. Biggest take away: Start early!
@danafarber.bsky.social
December 10, 2024 at 6:34 PM
Reposted by Sara Tolaney
ccortimd.bsky.social
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
December 13, 2024 at 6:05 AM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Meet Dr. Stefania Morganti, an Advanced Fellow at the Breast Oncology Center at @danafarber.bsky.social. Dr. Morganti earned her MD at the University of Pavia and specialized in medical oncology. Her research is aimed at developing patient-centered approaches to advance #BreastCancer treatment.
December 6, 2024 at 9:05 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases.
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
December 6, 2024 at 7:32 PM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Check out the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (November 25th- December 1st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
December 5, 2024 at 6:27 PM
Reposted by Sara Tolaney
antgiordanomd.bsky.social
Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24
December 6, 2024 at 9:15 AM
Reposted by Sara Tolaney
ptarantinomd.bsky.social
Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social
December 6, 2024 at 3:51 AM
Reposted by Sara Tolaney
dfcibreastonc.bsky.social
Dr. Abirami Natarajan and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss adjuvant #ribociclib in this
Annals of Oncology editorial.
👀 check it out here:
sciencedirect.com/science/arti...
December 5, 2024 at 8:30 PM
Reposted by Sara Tolaney
elisaagostinetto.bsky.social
Out in @TheLancetOncol
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer

PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group

@oncoalert.bsky.social

www.thelancet.com/journals/lan...
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...
These findings might suggest a potential advantage of nab-paclitaxel combined with trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy for patients with HER2-positive ...
www.thelancet.com
November 28, 2024 at 5:49 AM
Reposted by Sara Tolaney
sabcs.bsky.social
We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer
November 27, 2024 at 6:12 PM
Reposted by Sara Tolaney
tmprowell.bsky.social
Link for more info & to access FDA-ASCO Fellows’ Day Workshop application is here: asco.smapply.org/prog/Februar....

Apply by 12/4/24. Hope to see some of you in person or on Zoom for a day of #regulatory science #MedEd, #OncSky! 😃

#MedSky #healthpolicy #mentorship #OncoAlert
February 2025 FDA/ASCO Fellows' Day Workshop - Application Portal
asco.smapply.org
November 26, 2024 at 3:15 AM
Reposted by Sara Tolaney
maryamlustberg.bsky.social
Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc

doi.org/10.1093/jnci...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
doi.org
November 27, 2024 at 9:46 PM
Reposted by Sara Tolaney
ilanaschlam.bsky.social
Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight:
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
November 27, 2024 at 1:11 AM
Reposted by Sara Tolaney
erikahamilton9.bsky.social
We are going to be bringing #SABCS24 updates to #BlueSky too starting Dec 10th!

Many great colleagues on here including some amazing advocates.

@itsnotpink.bsky.social
@janicetnbcmets.bsky.social
@oncbrothers.bsky.social
@hoperugo.bsky.social
....and others!

@sabcs.bsky.social
#bcsm
November 26, 2024 at 10:18 PM